|
20 Sep 2025 |
Eris Lifesciences
|
Consensus Share Price Target
|
1639.60 |
1860.10 |
- |
13.45 |
buy
|
|
|
|
|
13 Jun 2017
|
Eris Lifesciences
|
ICICI Securities Limited
|
1639.60
|
|
|
|
IPO Subscribe
|
|
|
Ahmedabad based Eris Lifesciences (Eris) is a domestic branded formulations focused pharmaceutical company with emphasis on lifestyle related specialised therapeutic areas. The company was promoted by first generation entrepreneur Amit Bakshi in 2007. As on FY17, its product portfolio comprised 80 mother brand groups and is primarily focused on therapies that require the intervention of specialists and super specialists. The acute: chronic ratio was at 66:34 pertaining to FY17 revenues. The company derived ~77% of revenues from metro cities and class-1 towns....
|
|
13 Jun 2017
|
Eris Lifesciences
|
Ashika Research
|
1639.60
|
|
|
|
IPO Subscribe
|
|
|
The objects of the Offer are to achieve the benefits of listing the Equity Shares on the Stock Exchanges and for the sale of up to 28,875,000 Equity Shares by the Selling Shareholders. Further, Company expects that listing of the Equity Shares will enhance their visibility and brand image and provide liquidity to the shareholders. The Company will not receive any...
|
|
13 Jun 2017
|
Eris Lifesciences
|
SMC online
|
1639.60
|
|
|
|
IPO Note
|
|
|
Incorporated in 2007, Eris Lifescience Ltd is Ahmedabad, Gujrat based pharmaceutical company engaged in research, development, manufacturing and selling of select therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market (IPM). The product portfolio of the company comprised of 80 mother brand groups as of March 31, 2017. The product portfolio is primarily focused on therapeutic areas which require the intervention of specialists and super specialists such as cardiologists, diabetologists, endocrinologists and gastroenterologists. Sales in metro cities and class 1 towns, together accounted for 76.8% of its revenues in Fiscal 2017. Eris Lifescience own...
|